資源描述：
《食管癌術(shù)后聯(lián)合放化療對(duì)淋巴細(xì)胞亞群的影響》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫。
1、食管癌術(shù)后聯(lián)合放化療對(duì)淋巴細(xì)胞亞群的影響食管癌術(shù)后聯(lián)合放化療對(duì)淋巴細(xì)胞亞群的影響食管癌術(shù)后聯(lián)合放化療對(duì)淋巴細(xì)胞亞群的影響食管癌術(shù)后聯(lián)合放化療對(duì)淋巴細(xì)胞亞群的影響食管癌術(shù)后聯(lián)合放化療對(duì)淋巴細(xì)胞亞群的影響食管癌術(shù)后聯(lián)合放化療對(duì)淋巴細(xì)胞亞群的影響食管癌術(shù)后聯(lián)合放化療對(duì)淋巴細(xì)胞亞群的影響臨床和實(shí)驗(yàn)區(qū)學(xué)雜志2011年3月第10畚第5期?353?食管癌術(shù)后聯(lián)合放化療對(duì)淋巴細(xì)胞亞群的影響朱靜凌揚(yáng)張長松朱長太(常州市腫瘤醫(yī)院腫瘤實(shí)驗(yàn)室劉永萍董春雷孔穎澤江蘇常州213001)【摘要】目的探討食管癌術(shù)后放化療對(duì)患者細(xì)胞免疫的影響.方法應(yīng)用流式細(xì)胞儀
2、定量檢測(cè)73例食管癌患者外周血淋巴細(xì)胞亞群,共獲取術(shù)后不同時(shí)間點(diǎn)的139份血樣.結(jié)果術(shù)后不同治療方法對(duì)淋巴細(xì)胞亞群的絕對(duì)和相對(duì)定量結(jié)果均有影響.CD4+,CD8+T細(xì)胞絕對(duì)數(shù)各組均有統(tǒng)計(jì)學(xué)差異,術(shù)后間期延長的患者呈現(xiàn)更低的CD4/CD8.放療組對(duì)CD3+,CD4+和CD8+絕對(duì)數(shù)有影響.CIM+T細(xì)胞隨術(shù)后間期延長而降低,導(dǎo)致術(shù)后T細(xì)胞免疫功能失衡.結(jié)論術(shù)后聯(lián)合治療方式與CD4+T細(xì)胞相對(duì)定量相關(guān),提示食管癌術(shù)后聯(lián)合治療可能選擇性影響患者免疫功能.【關(guān)鍵詞】食管癌聯(lián)合化療淋巴細(xì)胞亞群Influenceofcombm~postop
3、erativeradiOtherapyandchemotherapyonperipherallymphocytesubsetsinpatientswithesophagealsqua-mOllScellcarcinoma.ZHUng,LING,ZHANGChang—song,eta1.ClinicalOncologyLaboratory,ChangzhouTumorHospital,Chang-zhouflan~u213001,China.【Abstract】0bjectiveToinvestigatetheinfluenceo
4、fpostoperativechemo—and/orradiotherapyoncellularimmunityinpatientswithe—sophagealsquamouscellcarcinoma(ESCC).MethodsAtotalof139bloodsampleswereobtainedatdifferenttimepointsrelativetosurgeryfrom73patientswithESCC.PeripheralTlymphocytesubsetsinresponsetochemotherapy,ra
5、diotherapy,andcombinedchemotherapyandradiotherapywereanalyzedbyflowcytometry.ResultsChangesintheabsolutequantityandrelativeproportionsoflymphocytesubsetswereobservedamongdifferentadjuvanttherapygroups.ThereweresignificantdifferencesintheabsolutecountsofCD4+andCD8+Tce
6、llsamonggroups.andalowerCD4/CD8ratiowasfoundinpatientsreceivedadjuvanttherapylongaftersurgery.Comp~edwithothergroups,radiotherapyaloneshowedpro—foundeffectontheabsolutecountofCD3+,CD4+,andCD8+Tcells.CD4+Tcelldecreasedwithtimeaftersurgeryandleadedtoapro-longedTcellimb
7、alance.ConclusionThesefindingsconfirmaninteractionbetweenadjuvanttherapyandperipheralCD4+Tcells,andimplythatadjuvanttherapymayhaveselectiveinfluenceoncellularimmuneafterESCCsurgery.【Keywords】ESCC;Adjuvanttherapy;Lymphocytesubset人體免疫系統(tǒng)理論上具有保護(hù)機(jī)體免于腫瘤的功能,因?yàn)樗梢栽缙诒O(jiān)測(cè)并清除腫瘤細(xì)胞
8、,或者保持腫瘤靜息狀態(tài),同時(shí)腫瘤細(xì)胞也具有腫瘤免疫逃逸的功能,因此二者的平衡在腫瘤治療中發(fā)揮重要作用¨J.淋巴細(xì)胞亞群在腫瘤中扮演細(xì)胞免疫的重要功能,CD4+和CD8+T細(xì)胞介導(dǎo)機(jī)體細(xì)胞免疫功能_3J.食管癌是高度惡性腫瘤之一,手術(shù),化療,放療是其主要治療方式,
